Samy Mohamady
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Samy Mohamady has a total of 45 co-authors. Here are the top co-authors by number of shared publications:
- Scott D. Taylor
University of Waterloo 200 University Ave. West
4 shared publications Abdalrahman Khalifa
Department of Pharmaceutical Chemistry, Faculty of Pharmacy, The British University in Egypt, El-Sherouk City, Cairo 11837, Egypt; The Center for Drug Research and Development (CDRD), Faculty of Pharmacy, The British University in Egypt, El-Sherouk City, Cairo 11837, Egypt; Department of Chemistry, Prairie View A&M University, Prairie View, TX 77446, USA
2 shared publicationsBassem H. Naguib
Department of Pharmaceutical Chemistry, Faculty of Pharmacy, The British University in Egypt, El-Sherouk City, Cairo 11837, Egypt; Pharmaceutical Organic Chemistry Department, Faculty of Pharmacy, Cairo University, Cairo, Egypt
2 shared publications- Hamed Ismail Ali
Department of Pharmaceutical Sciences, Rangel College of Pharmacy, Texas A&M Health Science Center, College Station, TX 77843, USA
2 shared publications - Muhammad I. Ismail
Department of Pharmaceutical Chemistry, Faculty of Pharmacy, The British University in Egypt, Al-Sherouk City, Cairo-Suez Desert Road, 11837 Cairo, Egypt
2 shared publications Samar M. Mogheith
Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Cairo University, Kasr El-Aini Street, 11562 Cairo, Egypt
2 shared publications
Latest Publications
- 12 June 2025
- Published by Elsevier in Bioorganic Chemistry
- Vol. 163, 108681
Design, novel one-pot green synthesis, and biological evaluation of pyrazolopyridine-congeners selectively targeting HER2+ breast cancer
- 12 June 2025
- Published by Elsevier in Bioorganic Chemistry
- Vol. 163, 108681
Design, novel one-pot green synthesis, and biological evaluation of pyrazolopyridine-congeners selectively targeting HER2+ breast cancer
- 20 November 2023
- Published by Elsevier in Bioorganic Chemistry
- Vol. 143, 106988
Tailored horseshoe-shaped nicotinonitrile scaffold as dual promising c-Met and Pim-1 inhibitors: Design, synthesis, SAR and in silico study
- 20 November 2023
- Published by Elsevier in Bioorganic Chemistry
- Vol. 143, 106988
Tailored horseshoe-shaped nicotinonitrile scaffold as dual promising c-Met and Pim-1 inhibitors: Design, synthesis, SAR and in silico study
- 6 May 2023
- Published by Elsevier in Bioorganic Chemistry
- Vol. 138, 106591
Isatin-pyrimidine hybrid derivatives as enoyl acyl carrier protein reductase (InhA) inhibitors against Mycobacterium tuberculosis
- 6 May 2023
- Published by Elsevier in Bioorganic Chemistry
- Vol. 138, 106591
Isatin-pyrimidine hybrid derivatives as enoyl acyl carrier protein reductase (InhA) inhibitors against Mycobacterium tuberculosis
- 17 April 2023
- Published by Wiley in European Journal of Organic Chemistry
- Vol. 26 (17)
Metal‐ and Catalyst‐Free Synthesis of 2‐Substituted‐Phthalimides Using 2‐(Arenesulfonyl)Phthalimide as Key Reagents
Phthalimide derivatives are important in medicinal chemistry, several phthalimidation methodologies have been developed. Here, we report a facile, metal‐free, and catalyst‐free method for the preparation of N‐phthalimides in good to excellent yield by reacting 2‐(arenesulfonyl)phthalimides with various amine substrates.
- 17 April 2023
- Published by Wiley in European Journal of Organic Chemistry
- Vol. 26 (17)
Metal‐ and Catalyst‐Free Synthesis of 2‐Substituted‐Phthalimides Using 2‐(Arenesulfonyl)Phthalimide as Key Reagents
Phthalimide derivatives are important in medicinal chemistry, several phthalimidation methodologies have been developed. Here, we report a facile, metal‐free, and catalyst‐free method for the preparation of N‐phthalimides in good to excellent yield by reacting 2‐(arenesulfonyl)phthalimides with various amine substrates.
- 6 August 2020
- Published by American Chemical Society (ACS) in ACS Omega
- Vol. 5 (32) , 20170-20186
Design, Synthesis, and Biological Evaluation of Novel 7H-[1,2,4]Triazolo[3,4-b][1,3,4]thiadiazine Inhibitors as Antitumor Agents
A series of novel anticancer hydrazinotriazolothiadiazine-based derivatives were designed based on the structure–activity relationship of the previously reported anticancer triazolothiadiazines. These derivatives were synthesized and biologically screened against full NCI-60 cancer cell lines revealing compound 5l with a potential antiproliferative effect. 5l was screened over 16 kinases to study its cytotoxic mechanism which showed to inhibit glycogen synthase kinase-3 β (GSK-3β) with IC50 equal to 0.883 μM and 14-fold selectivity over CDK2. Also, 5l increased active caspase-3 levels, induced cell cycle arrest at the G2-M phase, and increased the percentage of Annexin V-fluorescein isothiocyanate-positive apoptotic cells in PC-3 prostate cancer-treated cells. Molecular docking and dynamics were performed to predict the binding mode of 5l in the GSK-3β ATP binding site. 5l can be utilized as a starting scaffold for developing potential GSK-3β inhibitors.
- 6 August 2020
- Published by American Chemical Society (ACS) in ACS Omega
- Vol. 5 (32) , 20170-20186
Design, Synthesis, and Biological Evaluation of Novel 7H-[1,2,4]Triazolo[3,4-b][1,3,4]thiadiazine Inhibitors as Antitumor Agents
A series of novel anticancer hydrazinotriazolothiadiazine-based derivatives were designed based on the structure–activity relationship of the previously reported anticancer triazolothiadiazines. These derivatives were synthesized and biologically screened against full NCI-60 cancer cell lines revealing compound 5l with a potential antiproliferative effect. 5l was screened over 16 kinases to study its cytotoxic mechanism which showed to inhibit glycogen synthase kinase-3 β (GSK-3β) with IC50 equal to 0.883 μM and 14-fold selectivity over CDK2. Also, 5l increased active caspase-3 levels, induced cell cycle arrest at the G2-M phase, and increased the percentage of Annexin V-fluorescein isothiocyanate-positive apoptotic cells in PC-3 prostate cancer-treated cells. Molecular docking and dynamics were performed to predict the binding mode of 5l in the GSK-3β ATP binding site. 5l can be utilized as a starting scaffold for developing potential GSK-3β inhibitors.
- 24 July 2020
- Published by American Chemical Society (ACS) in ACS Omega
- Vol. 5 (30) , 18872-18886
Dual Targeting of VEGFR2 and C-Met Kinases via the Design and Synthesis of Substituted 3-(Triazolo-thiadiazin-3-yl)indolin-2-one Derivatives as Angiogenesis Inhibitors
The vascular endothelial growth factor receptor 2 (VEGFR2) and c-mesenchymal epithelial transition factor (c-Met) are members of receptor tyrosine kinases which have a crucial role in the process of angiogenesis. Isatin moiety is a versatile group that is shared in many compounds targeting both c-Met and VEGFR2 kinases. In this study, we designed and synthesized different derivatives of substituted 3-(triazolo-thiadiazin-3-yl)indolin-2-one derivatives (6a–y) as dual inhibitors for c-Met and VEGFR2 enzymes. Eight compounds 6a, 6b, 6e, 6l, 6n, 6r, 6v, and 6y were assessed for their anticancer activities against a panel of 58 cancer cell lines according to the US-NCI protocol. Compound 6b revealed the most effective antiproliferative potency (GI %), with broad-spectrum activity against different subpanels of the most NCI 58 tumor cell lines. An in vivo hen’s egg-chorioallantoic membrane (HET-CAM) angiogenic study was carried out for 21 compounds 6a, b, d, f, h, i, k–o, t, and 6x to check their mortality and toxicity. At 100 μM concentration, all compounds produced 100% mortality of the chick embryos. At 40 μM concentration, 13 compounds did not exhibit any detectable mortality (nontoxic) and revealed a potent antiangiogenic effect. Seven compounds 6b, 6d, 6f, 6n, 6o, 6t, and 6x significantly decreased the number of blood vessels, and compound 6b was the most effective antiangiogenic agent comparable to dexamethasone. Molecular docking studies were conducted for compound 6b to investigate its mode of interaction within the binding site of both c-Met and VEGFR2 kinases.
- 24 July 2020
- Published by American Chemical Society (ACS) in ACS Omega
- Vol. 5 (30) , 18872-18886
Dual Targeting of VEGFR2 and C-Met Kinases via the Design and Synthesis of Substituted 3-(Triazolo-thiadiazin-3-yl)indolin-2-one Derivatives as Angiogenesis Inhibitors
The vascular endothelial growth factor receptor 2 (VEGFR2) and c-mesenchymal epithelial transition factor (c-Met) are members of receptor tyrosine kinases which have a crucial role in the process of angiogenesis. Isatin moiety is a versatile group that is shared in many compounds targeting both c-Met and VEGFR2 kinases. In this study, we designed and synthesized different derivatives of substituted 3-(triazolo-thiadiazin-3-yl)indolin-2-one derivatives (6a–y) as dual inhibitors for c-Met and VEGFR2 enzymes. Eight compounds 6a, 6b, 6e, 6l, 6n, 6r, 6v, and 6y were assessed for their anticancer activities against a panel of 58 cancer cell lines according to the US-NCI protocol. Compound 6b revealed the most effective antiproliferative potency (GI %), with broad-spectrum activity against different subpanels of the most NCI 58 tumor cell lines. An in vivo hen’s egg-chorioallantoic membrane (HET-CAM) angiogenic study was carried out for 21 compounds 6a, b, d, f, h, i, k–o, t, and 6x to check their mortality and toxicity. At 100 μM concentration, all compounds produced 100% mortality of the chick embryos. At 40 μM concentration, 13 compounds did not exhibit any detectable mortality (nontoxic) and revealed a potent antiangiogenic effect. Seven compounds 6b, 6d, 6f, 6n, 6o, 6t, and 6x significantly decreased the number of blood vessels, and compound 6b was the most effective antiangiogenic agent comparable to dexamethasone. Molecular docking studies were conducted for compound 6b to investigate its mode of interaction within the binding site of both c-Met and VEGFR2 kinases.
- 1 January 2020
- Published by Elsevier in Bioorganic Chemistry
- Vol. 94, 103433
Discovery of 5-aryl-3-thiophen-2-yl-1H-pyrazoles as a new class of Hsp90 inhibitors in hepatocellular carcinoma
- 1 January 2020
- Published by Elsevier in Bioorganic Chemistry
- Vol. 94, 103433
Discovery of 5-aryl-3-thiophen-2-yl-1H-pyrazoles as a new class of Hsp90 inhibitors in hepatocellular carcinoma
- Open Access
- 15 November 2018
- Published by American Chemical Society (ACS) in ACS Omega
- Vol. 3 (11) , 15566-15574
Efficient One-Pot, Two-Component Modular Synthesis of 3,5-Disubstituted Pyrazoles
The pyrazole scaffold is one of the most prevalent and important tool in medicinal chemistry. Here, we report a method for preparing 3,5-diarylpyrazoles in good to excellent yield by reacting hydrazones of aryl aldehydes with substituted acetophenones in ethanol in the presence of dimethyl sulfoxide/cat. I2/cat. HCl. The reverse process, reacting hydrazones of substituted acetophenones with aryl aldehydes under the same conditions, also provides 3,5-diarylpyrazoles in good to excellent yields. Reaction of hydrazones of aldehydes with 2′-aryloxy ketones in the presence of cat. HCl in ethanol and the catalyst-free reaction of phenacyl bromides with hydrazones of aldehydes in ethanol also gave good to excellent yields of 3,5-diarylpyrazoles.
- 15 November 2018
- Published by American Chemical Society (ACS) in ACS Omega
- Vol. 3 (11) , 15566-15574
Open AccessEfficient One-Pot, Two-Component Modular Synthesis of 3,5-Disubstituted Pyrazoles
The pyrazole scaffold is one of the most prevalent and important tool in medicinal chemistry. Here, we report a method for preparing 3,5-diarylpyrazoles in good to excellent yield by reacting hydrazones of aryl aldehydes with substituted acetophenones in ethanol in the presence of dimethyl sulfoxide/cat. I2/cat. HCl. The reverse process, reacting hydrazones of substituted acetophenones with aryl aldehydes under the same conditions, also provides 3,5-diarylpyrazoles in good to excellent yields. Reaction of hydrazones of aldehydes with 2′-aryloxy ketones in the presence of cat. HCl in ethanol and the catalyst-free reaction of phenacyl bromides with hydrazones of aldehydes in ethanol also gave good to excellent yields of 3,5-diarylpyrazoles.
- 1 December 2016
- Published by Elsevier in Tetrahedron Letters
- Vol. 57 (49) , 5457-5459
One flask synthesis of 2′,3′-cyclic nucleoside monophosphates from unprotected nucleosides using activated cyclic trimetaphosphate
- 1 December 2016
- Published by Elsevier in Tetrahedron Letters
- Vol. 57 (49) , 5457-5459
One flask synthesis of 2′,3′-cyclic nucleoside monophosphates from unprotected nucleosides using activated cyclic trimetaphosphate